Claims
- 1. A transdermal dosage form comprising at least one active agent and at least one inactivating agent, wherein the inactivating agent is a cross-linking agent that is released upon disruption of the dosage form.
- 2. A transdermal dosage form of claim 1, wherein the transdermal dosage form is a transdermal patch.
- 3. A transdermal dosage form of claim 1, wherein the disruption of the dosage form occurs when the dosage form is solubilized, opened, chewed and/or cut apart.
- 4. A transdermal dosage form of claim 1, wherein the crosslinking agent is selected from the group consisting of polymerizing agent, photoinitiator, and aldehydes.
- 5. A transdermal dosage form of claim 4, wherein the aldehyde is formalin.
- 6. A transdermal dosage form of claim 4, wherein the polymerizing agent is selected from the group consisting of diisocyanate, organic peroxide, diimide, diol, triol, epoxide, cyanoacrylate, and a UV activated monomer.
- 7. A transdermal dosage form of claim 1 further comprising an antagonist.
- 8. A transdermal dosage form of claim 7, wherein the antagonist is an opiate antagonist, and the active agent is an opiate.
- 9. A transdermal dosage form comprising a matrix comprising at least one active agent and beads comprising at least one inactivating agent, wherein the beads are mixed into the matrix.
- 10. A transdermal dosage form of claim 9, wherein the transdermal dosage form is a transdermal dosage article or a transdermal dosage composition.
- 11. A transdermal dosage form of claim 9 further comprising an antagonist.
- 12. A transdermal dosage form of claim 9, wherein the beads are comprised of microscopic polysaccharide beads, starch beads, polyacetate beads, or liposomes.
- 13. A transdermal dosage form of claim 9, wherein the beads are dissolved upon contact with an aqueous solvent or a non-aqueous solvent.
- 14. A transdermal dosage form comprising a matrix comprising at least one active agent and a polymer complexed to at least one inactivating agent.
- 15. A transdermal dosage form of claim 14, wherein the transdermal dosage form is a transdermal dosage article or a transdermal dosage composition.
- 16. A transdermal dosage form of claim 14, wherein the polymer may be complexed to at least one antagonist.
- 17. A transdermal dosage form of claim 14, wherein the polymer is a crosslinked styrene divinyl benzene polymer.
- 18. A transdermal dosage form of claim 14, wherein the polymer may optionally be linked to a solid support.
- 19. A transdermal dosage form of claim 18, wherein the solid support is resin.
- 20. A transdermal dosage form of claim 14, wherein the inactivating agent and the antagonist uncomplex from the polymer in an ionic solvent.
- 21. A transdermal dosage article comprising a first layer comprising at least one active agent, an inactivating layer comprising at least one inactivating agent, and a solvent soluble membrane or solvent soluble layer.
- 22. A transdermal dosage form of claim 21, wherein the inactivating layer further comprises an antagonist.
- 23. A transdermal dosage form of claim 21, wherein the solvent soluble membrane or solvent soluble layer is comprised of hydroxy ethyl cellulose and hydroxypropylmethylcellulose.
- 24. A transdermal dosage form of claim 21, wherein the solvent is water.
- 25. A transdermal dosage form comprising at least one active agent and means for crosslinking said active agent upon disruption of the dosage form.
- 26. A transdermal dosage form of claim 25 wherein the transdermal dosage form is a transdermal patch.
- 27. A transdermal dosage form of claim 25 wherein said crosslinking means is a crosslinking agent that is released upon disruption of the dosage form.
- 28. A transdermal dosage form of claim 25, wherein the disruption of the dosage form occurs when the dosage form is solubilized, opened, chewed and/or cut apart.
- 29. A transdermal dosage form of claim 25, wherein the crosslinking agent is selected from the group consisting of polymerizing agent, photoinitiator, and aldehydes.
- 30. A transdermal dosage form of claim 29, wherein the aldehyde is formalin.
- 31. A transdermal dosage form of claim 29, wherein the polymerizing agent is selected from the group consisting of diisocyanate, organic peroxide, diimide, diol, triol, epoxide, cyanoacrylate, and a UV activated monomer.
- 32. A transdermal dosage form of claim 25 further comprising an antagonist.
- 33. A transdermal dosage form of claim 32, wherein the antagonist is an opiate antagonist, and the active agent is an opiate.
- 34. A transdermal dosage form comprising a matrix comprising at least one active agent and a polymer complexed to at least one inactivating means.
- 35. A transdermal dosage form of claim 34, wherein the transdermal dosage form is a transdermal dosage article or a transdermal dosage composition.
- 36. A transdermal dosage form of claim 34, wherein the polymer may be complexed to at least one antagonist.
- 37. A transdermal dosage form of claim 34, wherein the polymer is a crosslinked styrene divinyl benzene polymer.
- 38. A transdermal dosage form of claim 34, wherein the polymer may optionally be linked to a solid support.
- 39. A transdermal dosage form of claim 38, wherein the solid support is resin.
- 40. A transdermal dosage form of claim 34, wherein the inactivating agent and the antagonist uncomplex from the polymer in an ionic solvent.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application Ser. No. 60/287,875, filed May 1, 2001, and from U.S. Provisional Application Ser. No. 60/292,537, filed May 22, 2001, which are incorporated herein by reference in their entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US02/14073 |
4/30/2002 |
WO |
|
Provisional Applications (2)
|
Number |
Date |
Country |
|
60287875 |
May 2001 |
US |
|
60292537 |
May 2001 |
US |